Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2015 (2015), Article ID 498328, 13 pages
http://dx.doi.org/10.1155/2015/498328
Research Article

Atherogenic Cytokines Regulate VEGF-A-Induced Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Endothelial Cells

1Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA
2Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE 68178, USA
3Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE 68178, USA

Received 19 March 2015; Accepted 11 May 2015

Academic Editor: Hung-Fat Tse

Copyright © 2015 Izuagie Attairu Ikhapoh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics—2013 update: a report from the American Heart Association,” Circulation, vol. 127, pp. e6–e245, 2013. View at Google Scholar
  2. J. Doostzadeh, L. N. Clark, S. Bezenek, W. Pierson, P. R. Sood, and K. Sudhir, “Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE v drug-eluting stent,” Coronary Artery Disease, vol. 21, no. 1, pp. 46–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Mund, D. A. Ingram, M. C. Yoder, and J. Case, “Endothelial progenitor cells and cardiovascular cell-based therapies,” Cytotherapy, vol. 11, no. 2, pp. 103–113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. T. Kuswardhani and A. Soejitno, “Bone marrow-derived stem cells as an adjunctive treatment for acute myocardial infarction: a systematic review and meta-analysis,” Acta medica Indonesiana, vol. 43, no. 3, pp. 168–177, 2011. View at Google Scholar · View at Scopus
  5. D. Pankajakshan, V. Kansal, and D. K. Agrawal, “In vitro differentiation of bone marrow derived porcine mesenchymal stem cells to endothelial cells,” Journal of Tissue Engineering and Regenerative Medicine, vol. 7, no. 11, pp. 911–920, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. T. J. Burdon, A. Paul, N. Noiseux, S. Prakash, and D. Shum-Tim, “Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential,” Bone Marrow Research, vol. 2011, Article ID 207326, 14 pages, 2011. View at Publisher · View at Google Scholar
  7. L. Coultas, K. Chawengsaksophak, and J. Rossant, “Endothelial cells and VEGF in vascular development,” Nature, vol. 438, no. 7070, pp. 937–945, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Mayer, H. Bertram, W. Lindenmaier, T. Korff, H. Weber, and H. Weich, “Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation,” Journal of Cellular Biochemistry, vol. 95, no. 4, pp. 827–839, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, “Vascular endothelial growth factor (VEGF) and its receptors,” The FASEB Journal, vol. 13, no. 1, pp. 9–22, 1999. View at Google Scholar · View at Scopus
  10. J. Xu, X. Liu, Y. Jiang et al., “MAPK/ERK signalling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6, pp. 2395–2406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Cai, W. G. Jiang, A. Ahmed, and M. Boulton, “Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS,” Microvascular Research, vol. 71, no. 1, pp. 20–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Breuss, M. Cejna, H. Bergmeister et al., “Activation of nuclear factor-κB significantly contributes to lumen loss in a rabbit lliac artery balloon angioplasty model,” Circulation, vol. 105, no. 5, pp. 633–638, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Brull, H. E. Montgomery, J. Sanders et al., “Interleukin-6 gene -174G > C and -572G > C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 9, pp. 1458–1463, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Exner, M. Schillinger, E. Minar et al., “Interleukin-6 promoter genotype and restenosis after femoropopliteal balloon angioplasty: initial observations,” Radiology, vol. 231, no. 3, pp. 839–844, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Tanaka, G. Sukhova, D. Schwartz, and P. Libby, “Proliferating arterial smooth muscle cells after balloon injury express TNF-α but not interleukin-1 or basic fibroblast growth factor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 1, pp. 12–18, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Viswanathan, C. Strömberg, A. Seltzer, and J. M. Saavedra, “Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta,” Journal of Clinical Investigation, vol. 90, no. 5, pp. 1707–1712, 1992. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Kornowski, M. K. Hong, F. O. Tio, O. Bramwell, H. Wu, and M. B. Leon, “In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia,” Journal of the American College of Cardiology, vol. 31, no. 1, pp. 224–230, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. G. K. Gupta, T. Agrawal, M. G. Del Core, W. J. Hunter, and D. K. Agrawal, “Decreased expression of vitamin D receptors in neointimal lesions following coronary artery angioplasty in atherosclerotic swine,” PLoS ONE, vol. 7, no. 8, Article ID e42789, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. K. Gupta, K. Dhar, M. G. Del Core, W. J. Hunter, G. I. Hatzoudis, and D. K. Agrawal, “Suppressor of cytokine signaling-3 and intimal hyperplasia in porcine coronary arteries following coronary intervention,” Experimental and Molecular Pathology, vol. 91, no. 1, pp. 346–352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. I. Ikhapoh, C. J. Pelham, and D. K. Agrawal, “Synergistic effect of angiotensin II on vascular endothelial growth factor-A-mediated differentiation of bone marrow-derived mesenchymal stem cells into endothelial cells,” Stem Cell Research & Therapy, vol. 6, no. 1, p. 4, 2015. View at Google Scholar
  21. I. A. Ikhapoh, C. J. Pelham, and D. K. Agrawal, “Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells,” Differentiation, 2015. View at Publisher · View at Google Scholar
  22. G. K. Owens, M. S. Kumar, and B. R. Wamhoff, “Molecular regulation of vascular smooth muscle cell differentiation in development and disease,” Physiological Reviews, vol. 84, no. 3, pp. 767–801, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. C. George, “Stem cell therapy in acute myocardial infarction: a review of clinical trials,” Translational Research, vol. 155, no. 1, pp. 10–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., “Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,” Journal of the American Medical Association, vol. 308, no. 22, pp. 2369–2379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Forte, B. Rinaldi, L. Sodano et al., “Stem cell therapy for arterial restenosis: potential parameters contributing to the success of bone marrow-derived mesenchymal stromal cells,” Cardiovascular Drugs and Therapy, vol. 26, no. 1, pp. 9–21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Higuchi, H. Ohtsu, H. Suzuki, H. Shirai, G. D. Frank, and S. Eguchi, “Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology,” Clinical Science, vol. 112, no. 7-8, pp. 417–428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. R. M. Carey, X.-H. Jin, Z.-Q. Wang, and H. M. Siragy, “Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor,” Acta Physiologica Scandinavica, vol. 168, no. 1, pp. 65–71, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Latini, A. P. Maggioni, M. Flather, P. Sleight, and G. Tognoni, “ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials,” Circulation, vol. 92, no. 10, pp. 3132–3137, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Demers, A. Mody, K. K. Teo, and R. S. McKelvie, “ACE inhibitors in heart failure: what more do we need to know?” American Journal of Cardiovascular Drugs, vol. 5, no. 6, pp. 351–359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. H. D. White, P. E. G. Aylward, Z. Huang et al., “Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT),” Circulation, vol. 112, no. 22, pp. 3391–3399, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Saunders, G. Cable, and J. Neutel, “Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (inclusive) study,” Journal of Clinical Hypertension, vol. 10, no. 1, pp. 27–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Yoshiji, S. Kuriyama, and H. Fukui, “Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma: possible role of vascular endothelial growth factor,” Tumor Biology, vol. 23, no. 6, pp. 348–356, 2002. View at Publisher · View at Google Scholar · View at Scopus